BREAST CANCER

FDA fast-tracks oral SERD giredestrant for early ER+/HER2- breast cancer after phase 3 shows 30% fewer invasive recurrences.

"Sacituzumab govitecan plus pembrolizumab [led to] improvement in PFS2...despite the crossover design of the trial," said Eleonora Teplinsky, MD.

A PD-1/TIGIT bispecific antibody plus T-DXd yielded pathologic complete responses, avoiding need for further chemotherapy.

"The key finding is that more axillary surgery in itself does not improve survival in these patients," said Jana de Boniface, MD, PhD.

FDA extends camizestrant review as ctDNA-guided ESR1 switch sparks debate; new analyses debut at ASCO while Europe advances approval.

Explore how genomic assays guide personalized early-stage ER+/HER2- breast cancer treatment, weighing Oncotype, MammaPrint, menopausal status, and chemo decisions.

The approval of the TROP2-directed ADC datopotamab deruxtecan is supported by results from the phase 3 TROPION-Breast02 trial.

The neoadjuvant and adjuvant FDA indications for T-DXd in HER2+ breast cancer are based on the DESTINY-Breast11 and DESTINY-Breast05 trials, respectively.

Gedatolisib moves frontline in HR+/HER2– metastatic breast cancer, adding endocrine-sensitive patients and testing triplets vs ribociclib to boost PFS.

FDA fast tracks RPTR-1.201, a TCR bispecific immunotherapy for advanced triple-negative breast cancer, as RaPTR-101 tests safety and early efficacy.

VIKTORIA-1 shows gedatolisib plus fulvestrant, with or without palbociclib, boosts PFS after CDK4/6 therapy in PIK3CA-mutant breast cancer.

The FDA has approved the first PROTAC in any indication, supported by phase 3 VERITAC-2 data.

The FDA's ODAC voted 6-3 against camizestrant for HR+/HER2– breast cancer, citing concerns over the SERENA-6 trial design and a lack of overall survival data.

Real-world data show community oncology care links to longer survival in metastatic breast cancer and NSCLC, beating national benchmarks.

Bayesian modeling links residual cancer burden shifts to survival, helping neoadjuvant breast cancer trials and FDA approvals predict real benefit.

Afuresertib plus fulvestrant cuts progression risk in HR+/HER2– metastatic breast cancer with PI3K/AKT/PTEN alterations, with manageable safety.

NCCN adds mammogram AI risk scoring; a 1.7% five‑year cutoff now prompts earlier screening and optional MRI/ultrasound.

The DAISY trial shows that HER2DX and DNADX genomic assays can predict T-DXd response in metastatic breast cancer by measuring HER2 levels and DNA instability.

Study finds risk-reducing mastectomy in BRCA1/2 carriers significantly cuts cancer risk but offers no overall survival benefit over intensive surveillance.

Victoria Rizk, MD, explores genomic assays to refine adjuvant therapy and capture clinical real-world evidence in breast cancer care.

Phase 2 TBCRC049 trial results show tucatinib triplet therapy improves survival in HER2+ breast cancer patients with leptomeningeal metastasis.

Genomic assays guide adjuvant therapy in HR-positive, HER2-negative breast cancer, clarifying who benefits from chemo by age, nodal status, and risk score.

Data presented at ESMO Targeted Anticancer Therapies Congress 2026 support ongoing phase 3 evaluation.

New HER2+ breast cancer trials refine chemo and antibody use—cutting toxicity with de‑escalation, while escalating high‑risk patients with T‑DXd.